Bristol-Myers Squibb (BMY) vs BeOne Medicines (ONC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed BeOne Medicines (ONC) over the past year, gaining 33.7% versus a gain of 6.6%. Over five years, BMY leads with a +2.3% price change compared with +1.6% for ONC. Bristol-Myers Squibb is the larger company by market cap ($120.34 billion vs $38.78 billion), about 3.1 times the size, while BeOne Medicines is growing revenue faster (+40.2% vs -0.2%).
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (8.9x vs 33.2x for BeOne Medicines). Bristol-Myers Squibb pays a dividend yielding 4.26%, while BeOne Medicines does not currently pay one. Bristol-Myers Squibb converts more of its revenue into profit, with a net margin of 14.6% versus 5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | ONC |
|---|---|---|
| Share price | $58.91 | $340.85 |
| Market cap | $120.34B | $38.78B |
| 1-day change | -1.32% | -6.37% |
| YTD return | +10.68% | +19.82% |
| 1-year return | +33.68% | +6.56% |
| 5-year return | +2.30% | +1.56% |
| P/E ratio (TTM) | 12.98 | 60.97 |
| Forward P/E | 8.94 | 33.25 |
| EPS (TTM) | $4.54 | $5.59 |
| Dividend yield | 4.26% | 0.00% |
| Annual dividend | $2.51 | $0.00 |
| Revenue (latest FY) | $48.19B | $5.34B |
| Revenue growth (YoY) | -0.22% | +40.23% |
| Net income (latest FY) | $7.05B | $286.93M |
| Gross margin | 71.08% | 87.49% |
| Operating margin | — | 8.37% |
| Net margin | 14.64% | 5.37% |
| 52-week high | $68.64 | $385.22 |
| 52-week low | $42.52 | $253.95 |
| Distance from 52-week high | -14.18% | -11.52% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +12.32% | +27.68% |
| Average volume | 11.22M | 388.88K |
| Shares outstanding | 2.04B | 104.92M |
| Employees | 32,500 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bristol-Myers Squibb is about 3.1 times larger than BeOne Medicines by market value ($120.34B vs $38.78B).
- BMY has outperformed ONC by 27.1 percentage points over the past year.
- BeOne Medicines trades at a higher earnings multiple (61.0x vs 13.0x trailing P/E).
- Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.26% vs 0.00%).
- Bristol-Myers Squibb is more profitable, keeping 14.6 cents of every revenue dollar as net income versus 5.4 cents for BeOne Medicines.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs -0.22%).
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
BMY vs ONC FAQ
Which is bigger, Bristol-Myers Squibb or BeOne Medicines?
Bristol-Myers Squibb (BMY) is larger, with a market capitalization of $120.34B compared with $38.78B for BeOne Medicines (ONC).
Which stock has performed better over the past year, BMY or ONC?
BMY returned +33.68% over the past 12 months, compared with +6.56% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMY or ONC?
BMY has the lower trailing P/E at 13.0, versus 61.0 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bristol-Myers Squibb or BeOne Medicines?
Bristol-Myers Squibb pays a dividend yielding 4.26%, while BeOne Medicines does not currently pay a regular dividend.
Are Bristol-Myers Squibb and BeOne Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.